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Introduction
COVID-19, caused by the coronavirus SARS-CoV-2, has be-
come pandemic. The impact of SARS-CoV-2 infection on the 
immune system and its modulation or suppression by phar-
macological intervention has been dissected in detail with 
regards to clinical implications of the various cytokines and 
cellular functions affected [1]. A further level of complexity 
opens up as soon as we look at diseases whose pathogene-
sis and therapy involve different immunological signaling 
pathways, which are potentially affected by COVID-19. 
Medical treatments must often be reassessed and questioned 
in connection with this infection. However, there is still con-
siderable uncertainty in this regard and we are currently in 
a phase of almost exponentially growing data on various di-
seases in the context of SARS-CoV-2 infections. The medi-
cal knowledge as well as the literature on COVID-19 and its 
treatment options is growing at an overwhelming pace [2–5].
This article focusses on common chronic inflammato-
ry skin diseases with complex immunological pathogenesis: 
psoriasis, eczema including atopic dermatitis, type I allergies, 
autoimmune blistering and inflammatory connective tissue 
diseases, vasculitis, and skin cancers. Since several other in-
flammatory skin diseases display related or comparable im-
munological reactions, clustering of the various inflammato-
ry dermatoses into six disease patterns was recently proposed 
[6]. Thus, following these patterns of skin inflammation, our 
review may supply treatment recommendations and thought-
ful considerations for disease management even beyond the 
most frequent diseases discussed here (Table 1).
SARS-CoV-2 and psoriasis
Like other respiratory viral infections, SARS-CoV-2 infection 
may aggravate psoriasis [7]. Of practical relevance is the 
question whether antipsoriatic treatments increase the risk of 
infection with SARS-CoV-2 or aggravate the course of CO-
VID-19 disease. Several aspects need to be considered in this 
discussion:
– Patients with untreated psoriasis and/or psoriatic arth-
ritis (PsA) have a 1.5 fold increased risk of severe infec-
tions compared to control individuals [8–10] and thera-
peutic normalization of an intrinsically aberrant immune 
response may improve the host defense against infection.
– The immune response to SARS-CoV-2 is complex; eli-
mination of the virus is associated with an innate and 
adaptive immune response involving T cells, NK cells, 
probably B cells and mediators such as IL-12, IL-15, in-
terferon-α/β and -γ. In a small subgroup of patients with 
severe COVID-19 and persistent virus replication, a hy-
perinflammatory response may develop with overexpres-
sion of IL-6, TNFα, IL-17A and other cytokines that are 
also targets of psoriasis therapies [11]. In this situation, 
cytokine inhibition may be beneficial and/or have a pre-
ventive effect [12]. The JAK1/2 inhibitor baricitinib and 
cyclosporine may increase the risk of viral infections, but 
may also inhibit viral entry and replication, respectively 
[13, 14].
–	 Some risk factors for a more severe course of COVID-19 
including arterial hypertension, type II diabetes, smoking 
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Table 1 Overview of dermatological and allergological diseases and the established or suspected effects of SARS-CoV-2 infec-
tion/COVID-19 on disease severity. Approved therapeutic compounds are listed as well as recommendations for continued use 
and novel introduction of systemic treatment.
Disease Impact of COVID-19 










vel introduction of  
systemic treatment
Psoriasis Possible aggravation 
of disease
– infliximab, adalimumab, 
certolizumab, etanercept
– ustekinumab, guselkumab, 
risankizumab, tildrakizumab









No distinction is being made 
between labeled treatment 
options.
Targeted therapy probably 
preferable over conven-
tional systemic immune 
modulation









Retinoids and targeted thera-
py with dupilumab probably 
preferable over conventional 
systemic immune  
modulation
Allergic bronchial 













New therapies may be star-













when needed to avoid 
uncontrolled flares
Postpone rituximab to delay 
B cell depletion during peak 
COVID-19 when possible and 













Introduce novel treatment 
regimen as needed
Vasculitis Aggravation of disea-








pressants for vasculitis 
treatment should be 
even more restricted
Use of immunosuppressants 
for vasculitis treatment 
should be even more  
restricted.
Postpone rituximab and cyclo-
phosphamide to delay immu-
nosuppression during peak 
COVID-19 when possible and 
consider use of IVIG instead






dulatory therapy  
without changes
Introduce novel treatment 
regimen as needed
Abbr.: GCS, glucocorticosteroids, IVIG, intravenous immunoglobulins.
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and overweight are more common among psoriasis 
patients [15]. On the other hand, there is increasing 
evidence that successful treatment of psoriasis improves 
cardiovascular comorbidity [16].
–	 Most studies and registries have not demonstrated 
a significantly elevated risk of viral or respiratory 
tract infections in systemically treated patients with 
psoriasis [15].
In light of this complex discussion, national and interna-
tional recommendations suggest not to delay the onset of 
appropriate systemic therapy and not to stop such therapy 
in patients without symptoms [17]. No significant differen-
tiation is being made between labeled treatment options. As 
a precautionary measure in patients with typical symptoms 
of COVID-19, systemic therapy should not be started and 
an existing therapy paused until a possible SARS-CoV-2 
infection has been excluded or resolved. Clinical evidence 
based on larger cohorts is only beginning to emerge. In one 
retrospective Italian study comparing patients with psoria-
sis on systemic therapy (n  =  1,193) with the background 
population of Lombardy since March 2020, the authors re-
ported a higher rate of symptomatic SARS-CoV-2 infection, 
self-quarantine (n  =  17) and hospitalization (n  =  5) for pa-
tients on biologics, but no increased risk of ICU admission 
or death [18]. In another Italian multicenter study, patients 
with psoriasis on biologics (n  =  5,206) were followed bet-
ween February 20th and April 1st 2020 [19]. There were no 
COVID-19-related deaths and the hospitalization rate was 
similar to that observed in the general population. Together 
with an earlier case series from New York City (n  =  86) 
[20], these findings support the above recommendations 
and should reassure patients with psoriasis and their trea-
ting physicians.
SARS-CoV-2, atopic dermatitis and other 
types of eczema
Although respiratory and cutaneous viral infections may wor-
sen or complicate atopic dermatitis and other types of ecze-
ma [21], data on effects of SARS-CoV-2 infection on eczema 
patients have not been published. Since T cells are centrally 
involved in the complex immuno-pathophysiology of eczema 
and associated diseases, SARS-CoV-2 infections may be of 
special concern in eczema patients with comorbid diseases 
such as asthma/chronic obstructive lung disease, eosinophi-
lic esophagitis, or severe allergies [22]. SARS-CoV-2-induced 
lymphopenia may hamper antiviral immunity and currently 
serves as a biomarker and a possible target for intervention 
by stimulation of lymphocyte proliferation or prevention of 
apoptosis to reduce the risk of severe disease [22]. Prelimi-
nary data points towards a direct infection of T lymphocytes 
with SARS-CoV-2, which may also cause cytopathic effects 
on infected T cells [23].
Following the sanitary recommendations for more fre-
quent hand washing and disinfection procedures during the 
pandemic, the prevalence of hand eczema is rising signifi-
cantly, even among persons not previously affected [24, 25]. 
Basic topical treatment with emollients, as well as specific 
treatment with topical corticosteroids and calcineurin inhi-
bitors should be initiated or continued according to current 
guidelines without any specific requirements, including UV-
light therapies. Since exacerbations of the skin disease may 
negatively affect the patients’ immunity, systemic treatment 
in eczema patients should be continued for all immune-mo-
dulating drugs including immuno-suppressive therapy, as 
consented and advised by the European Task Force on Ato-
pic Dermatitis (ETFAD) [26].
If a patient on systemic treatment is diagnosed with 
COVID-19, interdisciplinary risk assessments are necessary 
on whether to continue or pause systemic treatment, preferably 
in tertiary care centers [27]. In atopic dermatitis, immune- 
modulating medication may also control the severity of as-
thma/chronic obstructive lung disease and other comorbid 
conditions. Hence, termination of a stable treatment regi-
men with immune-modulating drugs may not be beneficial 
[28]. However, in patients with exclusive skin disease such 
as hand eczema, pausing of immune-modulating therapies 
seems to be less problematic in case of COVID-19, since 
flare-ups of the skin disease may be acceptable during the 
critical time of the viral infection. Whenever immune-modu-
lating therapy is stopped, patients need to be supplied with 
ample topical treatment and detailed instructions to control 
the skin disease for the following weeks. Close monitoring 
of comorbid diseases is important in these individuals. 
Targeting specific cytokines may even benefit patients with 
COVID-19, since therapeutic cytokine blockade without 
affecting viral clearance may inhibit hyper-inflammatory 
host responses [11].
If patients need to be started on systemic treatment for 
different types of eczema during the pandemic, exclusively 
anecdotal clinical data may support the following theoreti-
cal considerations. In general, conventional systemic immu-
ne-modulating drugs such as glucocorticoids, cyclosporine, 
azathioprine, or methotrexate affect the cellular immune 
response, mainly via inhibition of lymphocyte function and 
activation. Retinoids or type II immune response-direc-
ted therapies such as dupilumab affect the immune defense 
against viral infection to a lesser degree and may therefore 
be preferred [29]. Patients treated with dupilumab showed 
no increase in systemic infections, and occurrence of eczema 
herpeticum was significantly reduced in comparison to pla-
cebo treatment.
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SARS-CoV-2 and type I allergies
IgE-mediated type I allergic diseases affect up to 25 % of 
the population and dealing with these common diseases 
during the pandemic is necessary. The following comments 
refer to allergic bronchial asthma, allergic rhinitis and 
anaphylaxis.
Diagnosis of a type I allergy should currently focus pri-
marily on in vitro tests, if possible. Exceptions are drug and 
food intolerance reactions, as only few reliable in vitro tests 
are available. Skin prick tests and provocation tests with ae-
rosols (e.g. rhinomanometry) should only be performed after 
a strict indication and with sufficient protection of the per-
sonnel. Gloves, protective goggles, gowns and FFP2/FFP3 re-
spiratory masks should be worn to prevent the transmission 
of droplets and direct contact [30–32]. If this is not possible, 
the test should not be performed. To optimize the use of per-
sonal protective equipment in the event of inadequate supply, 
personnel should be assigned to specific tasks and procedures 
should be performed in specially designated areas.
Considerations for therapy of patients with type I 
allergic diseases
– Symptomatic topical antiallergic treatment, including 
topical corticosteroids, should be initiated or continued 
without restriction according to patient needs.
–	 Systemic antihistamines and leukotriene antagonists may 
be initiated or continued without restriction as needed. 
There is no evidence that this could adversely affect the 
susceptibility to infection or the course of SARS-CoV-2 
infection.
–	 Systemic corticosteroid therapy, especially at a dose of 
more than 10 mg/d, should be avoided or used only after 
a very strict indication and if possible only for a short 
period.
– The treatment of allergic bronchial asthma, nasal polyps 
or rarely anaphylactic reactions with biologicals should 
be continued. New therapies may be started, since no 
specific risk has been identified in SARS-CoV-2 infected 
patients [33].
–	 Anaphylactic shock should be treated acutely with 
epinephrines according to the current guidelines.
– The indication for administration of high-dose cortico-
steroids should be strictly defined, especially since the 
efficacy of corticosteroids in anaphylaxis is not clear.
–	 Specific subcutaneous or sublingual immunotherapy can 
be continued in symptom-free and healthy patients, and 
the treatment regimen should not be interrupted. In case 
of symptoms such as fever, unclear cough or reduced ge-
neral condition, immunotherapy should be suspended 
and continued at a later (symptom-free) time [34].
–	 In the case of interruption of subcutaneous immuno-
therapy (SCIT), the dose of SCIT should be adjusted 
according to the manufacturer’s recommendations. Re-
commencement of sublingual immunotherapy should be 
performed under medical supervision.
SARS-CoV-2 and autoimmune blistering 
dermatoses
Autoimmune blistering dermatoses (AIBD) are a heteroge-
neous group of potentially life-threatening disorders that 
characteristically present with blisters and erosions on the 
skin and/or mucous membranes near the outer skin surface 
[35–38]. Patients with AIBD likely belong to the COVID-19 
risk group [39]. An increased risk is arguably due to the long-
term use of corticosteroids, immunosuppressive adjuvants 
and rituximab [40]. In addition, the advanced age of patients 
with pemphigoid diseases, which accounts for two thirds of 
AIBDs in Europe and Northern America, is another major 
risk factor [36, 41]. Whether SARS-CoV-2 can enter through 
uncovered erosive skin lesions or oropharyngeal erosions can 
be debated.
The AIBD task force of the European Academy of Der-
matology and Venereology (EADV) has provided patient 
information, in addition to general advice on SARS-CoV-2, 
on how to take immunosuppressive drugs and on general 
precautions [42]. Patient recommendations in German can 
be accessed via the websites of the Deutsche Dermatologi-
sche Gesellschaft [32] and the Pemphigus und Pemphigoid 
Selbsthilfegruppe e.V. [43]. These are in line with interna-
tional expert recommendations and the International Pem-
phigus and Pemphigoid Foundation [44–46]. Some authors 
suggest to postpone rituximab to delay immunosuppression 
during peak COVID-19 and to use intravenous immunoglo-
bulins (IVIG) instead [46]. The latter have shown promise in 
severe COVID-19 [35, 47]. Others propose to maintain im-
munomodulatory therapy when needed to avoid uncontrolled 
flares with high morbidity and mortality. In COVID-19 pa-
tients with AIBD, immunosuppressants may be interrupted, 
and prednisone equivalent > 10 mg/d reduced, while topical 
corticosteroids, prednisone (≤ 10 mg/d), dapsone (with nor-
mal hemoglobin levels), doxycycline/tetracycline, colchicine, 
and IVIG can be continued [45].
Several clinical studies for the treatment of COVID-19 
are currently ongoing including the use of inhibitors of 
pro-inflammatory IL-6, IL-1α, and JAK1/2. These medi-
ators are, however, probably not centrally involved in the 
pathophysiology of AIBD [35, 36, 48]. In contrast, C5 ac-
tivation has been identified as crucial for lesion formation 
in experimental bullous pemphigoid and mucous membrane 
pemphigoid [49–51]. Since inhibition of C5 may result in 
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immediate clinical improvement of severe COVID-19 [52], 
its blockade may alleviate both, COVID-19 and pemphigoid 
diseases. Overall, beneficial anti-inflammatory effects should 
be weighed up against the potentially detrimental effects of 
inhibiting antiviral immunity [53].
So far, seven Italian AIBD patients with COVID-19 have 
been published [54–56]. Of the four patients with bullous 
pemphigoid who had to be hospitalized due to severe CO-
VID-19, three died, while one recovered [55]. In a survey by 
the AIBD task force of the EADV, 56 AIBD patients inclu-
ding 13 (23 %) fatal cases with COVID-19 were identified in 
51 centers from 22 countries worldwide until April 30, 2020. 
While no centers from China or the USA were included, most 
cases were reported from Iran and France. To gather more 
information on potential risk factors, a registry for AIBD pa-
tients with COVID-19 has been launched by the AIBD task 
force of the EADV [57].
SARS-CoV-2 and inflammatory 
connective tissue disease (collagenoses)
Systemic autoimmune diseases such as lupus erythematosus 
(SLE) or systemic sclerosis (SSc) are associated with increased 
IL-6, TNFα, IL-17 and IL-23 that induce auto reactive 
T-cells and autoantibodies. Only few data are available on 
SLE and SSc, so far none on cutaneous LE, morphea or 
dermatomyositis [58].
Recently, the clinical course of COVID-19 in 17 SLE pa-
tients was reported [59]. All patients received long-term hy-
droxychloroquine (HCQ), 71 % prednisone below 10 mg/d 
and 41 % immunosuppressants. During COVID-19, a higher 
rate of dyspnea, headache and diarrhea was detected in SLE 
patients compared to a previously reported Chinese general 
population from the Wuhan area [33, 60]. The majority of 
patients (76 %) developed viral pneumonia, 65 % with re-
spiratory failure and 29 % with acute respiratory distress 
syndrome. All patients were hospitalized, and two patients 
died during the 4-weeks observation period. None of the SLE 
patients showed clinical signs or deterioration of LE during 
COVID-19. In another study on 165 Italian SLE patients, 
clinical data on COVID-19 contact and infection were col-
lected [61]. 77 % of patients were treated with HCQ, 25 % 
with mycophenolic acid and 7 % with other immunosuppres-
sants. Twelve patients (7.2 %) developed COVID-19. Only 
one patient with confirmed infection and severe SLE had to 
be admitted to hospital with ICU treatment and non-invasive 
ventilation. Seven other SLE patients did not develop any 
symptoms of infection despite contact with COVID-19 pa-
tients. These early findings document the course of SARS-
CoV-2 infection in SLE and suggest that long-term intake of 
HCQ does not prevent severe COVID-19, nor does standard 
treatment affect the disease course. The relevance of HCQ is 
still much-debated [62–64] and respective trials have been 
stopped. Yet, the current shortage of the drug poses a serious 
hazard to SLE patients as a stable and effective treatment 
of the disease is recommended to minimize consequences of 
COVID-19.
A number of reports encompassing 201 COVID-19 
patients described acro-ischemic lesions resembling chilb-
lain LE [65]. In a larger retrospective case series with 132 
patients from Spain (mean age 19.9 years), 41 % had close 
contact to a confirmed COVID-19 patient, 14.4 % were cli-
nically diagnosed, but only two tested positive by PCR [66]. 
A chilblain-like pattern was found in 72 %, an erythema 
multiforme-like pattern in 28 % of the patients. All published 
patients had mild infectious disease and mostly developed 
cutaneous lesions up to three weeks after clinical symptoms 
suggestive of COVID-19. Cutaneous lesions may be induced 
by a SARS-CoV-2 infection-associated vasculopathy [67]. 
Only recently, relations to Kawasaki syndrome were described 
which is discussed in the next section on vascular changes.
A potentially high-risk group for developing severe CO-
VID-19 are patients with systemic sclerosis and interstitial 
lung disease (SSc-ILD). A case report described a 57-year old 
female with SSc-ILD and SARS-CoV-2 infection [68]. Tocili-
zumab (anti-IL-6 receptor antibody) was initiated four weeks 
prior to SARS-CoV-2 infection, which presented with mild 
symptoms. Larger trials are underway to evaluate the risks 
and benefits of tocilizumab in COVID-19 [69].
SARS-CoV-2 and vascular changes  
and diseases
Many case reports and case series observed “vascular skin 
symptoms” in COVID-19 patients. A study from France 
considering 14 confirmed SARS-CoV-2 patients reported 
acral chilblain- and livedo-like lesions as well as purpura 
[70]. Case reports on at least clinically confirmed vasculitis 
of small vessels or immune-complex vasculitis are rare [71]. 
More (including histological) evidence exists on occlusive 
vasculopathies, especially on acral chilblain-like dermato-
ses, which appear to accumulate in patients with COVID-19 
[72]. Histologically, they show occlusive vasculopathy rather 
than actual vasculitis. Livedo-like lesions and necrosis occur-
red in 6 % of the cases in one study and mostly affected elder-
ly patients with severe disease [65, 72]. Another report from 
France described acral lesions in 142 of 277 patients; 75 % of 
these presented with chilblain-like lesions [73]. In children, 
acral lesions mimicking perniones have attracted attention 
during the pandemic as well [74, 75]. Thus, chilblain-like 
lesions could be a sign of pauci-symptomatic SARS-CoV-2 
infection [70, 73].
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Of particular note are the recent cases of SARS-CoV-2-as-
sociated Kawasaki disease. Previously, this disease has been 
suspected to be associated with yet unidentified infectious 
triggers that provoke an intense proinflammatory response 
in genetically predisposed patients [76, 77]. In a study from 
Bergamo, Italy, Kawasaki-like disease was found 30-fold 
more often in children after start of the COVID-19 pande-
mic than before. Affected children were relatively older, pre-
sented with a higher rate of cardiac involvement and macro-
phage activation syndrome resulting in arterial hypotension 
and peripheral hypoperfusion than children diagnosed with 
Kawasaki disease before the COVID-19 pandemic [78–80]. 
Interestingly, the majority of the Kawasaki patients were ne-
gative for SARS-CoV-2 nucleic acid testing but all except two 
were positive for IgG/IgM antibodies to SARS-CoV-2 [78, 
79]. It was hypothesized that the mounting of an immune re-
sponse against the virus rather than the initial infection itself 
had been responsible for Kawasaki disease, suggesting that it 
is a post-infectious, possibly immune complex-mediated in-
flammatory syndrome [78, 80]. Treatment with intravenous 
immunoglobulins and glucocorticoids led to disease control 
in most patients [78, 80].
During the COVID-19 pandemic, the use of immuno-
suppressants for vasculitis treatment should be even more 
restricted when there is no sufficient evidence for their effi-
cacy as in most cases of IgA vasculitis or polyarteriitis no-
dosa cutanea. However, they must not be stopped abruptly 
or prophylactically in ANCA-associated and other severe 
systemic vasculitides. During the peak of the pandemic, 
162 Italian patients with previously diagnosed large vessel 
vasculitis (67 with Takayasu arteritis, 95 with giant cell 
arteritis) on treatment were surveyed [81]. Four patients 
had a microbiological diagnosis of SARS-CoV-2 infection, 
and two of them required hospitalization from which both 
fully recovered. Importantly, their vasculitis treatment was 
initiated before the SARS-CoV-2 outbreak (including toci-
lizumab [n  =  53], methotrexate [n  =  51], infliximab [n 
=  25]), and it was not stopped or reduced indicating that 
immunosuppression did not necessarily result in negative 
outcomes [81].
SARS-CoV-2 and skin cancer
The current COVID-19 pandemic also presents several chal-
lenges for the daily care of patients with skin cancer. The first 
challenge is to protect individuals with advanced disease (e.g. 
metastatic melanoma or carcinoma as well as late stage cuta-
neous lymphoma). These patients could be at above-average 
risk of SARS-CoV-2 infections due to systemic immunosup-
pression. This view is supported by publications, according 
to which cancer patients have a higher risk of SARS-CoV-2 
infections as well as of more severe courses of COVID-19 
[82–84]. However, these reports were hampered by small 
cohort sizes and limited clinical information. A more recent 
multi-center study revealed that patients with hematological 
malignancies, lung cancer or metastatic disease had the hig-
hest rates of severe events during COVID-19 and the highest 
death rate [85]. Detailed data assessing the risk of COVID-19 
for patients with advanced skin cancer are not available yet. 
Therefore, individual decisions should be made adapted to 
the patient's current health situation. A second challenge is 
to maintain regular services for skin cancer patients because 
many fear to acquire a SARS-CoV-2 infection in the hospital 
and therefore cancel their appointments. At the same time, 
government regulations and supply shortages have transiently 
limited the access of patients to regular health services [86]. 
This has led to concerns of some patients that their urgently 
needed treatments are postponed during the pandemic. It is 
therefore important to balance the necessity of skin cancer 
treatment with the potential morbidity and mortality due to 
an infection with SARS-CoV-2 on an individual basis [87].
The European Society for Medical Oncology (ESMO) as 
well as several other oncology societies have published guide-
lines for cancer patient management during the COVID-19 
pandemic [88, 89]. According to the ESMO guidelines, all 
cancer patients undergoing surgery, radiotherapy, chemothe-
rapy, or immunotherapy should be regularly tested for SARS-
CoV-2 infections before each treatment cycle. In the case of 
melanoma, patients with a new diagnosis of invasive primary 
cancer or with complications during targeted therapies or 
immunotherapies for inoperably advanced stage III or IV di-
sease should be prioritized for regular visits and continuous 
treatment [88]. Especially patients treated with checkpoint 
inhibitors need to be carefully controlled for COVID-19 
symptoms since some side effects such as autoimmune pneu-
monitis cannot easily be differentiated from progressive 
COVID-19 disease.
In Germany, a task force consisting of the Deutsche 
Krebsforschungszentrum (DKFZ), the Deutsche Krebshilfe 
and the Deutsche Krebsgesellschaft is continuously docu-
menting the effects of the COVID-19 pandemic on the care of 
cancer patients. So far, there is no measurable shortage in the 
care of these patients. However, the large number of cancel-
led appointments could reduce the diagnosis of early cancer 
stages, which could perhaps later translate into an increased 
number of more advanced stages. It is therefore important 
to explain to patients that the fear of SARS-CoV-2 infection 
should not prevent them from potentially life-saving visits to 
the doctor.
Conclusions
Generally, patients who feel ill with typical respiratory sym-
ptoms should be advised to have an initial telephone or video 
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consultation, and for the time being no careless visits to the 
practice or hospital should be arranged. The medical knowled-
ge as well as diagnostic and therapeutic recommendations on 
COVID-19 and its impact on dermatological and allergo-
logical diseases may change rapidly and need to be updated 
regularly. Since tremendous efforts are undertaken to impro-
ve our understanding and to consolidate optimal treatment 
regimens of COVID-19 patients, we encourage physicians 
to check regularly the homepages and recommenda tions of 
the different national and European societies for updates on 
patient management during the pandemic.
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